RCS - CRISM Therapeutics - Delivery Method Validated in Peer Reviewed Journal

CRISM' TherapeuticsAnnouncement

03/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240903:nRSC5932Ca&default-theme=true

RNS Number : 5932C  CRISM Therapeutics Corporation  03 September 2024

 

3 September 2024

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Drug Delivery Method Validated in Peer Reviewed Journal

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs, is pleased to
confirm that a recent peer reviewed research article, Local Delivery  of
Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe Route of
Administration, demonstrated that the local delivery of the chemotherapy drug
irinotecan directly into the border of the resection margin after a tumour has
been removed offers a safe route of administration for glioblastoma patients
with none of the normal side effects associated with traditional chemotherapy
delivered  by injection or orally.

The research article, in the journal Cancers, can be viewed at:
https://www.mdpi.com/2072-6694/16/17/3008
(https://urldefense.com/v3/__https:/www.mdpi.com/2072-6694/16/17/3008__;!!H_q-o1I4kFo!mtvjrZNlZ14KPGGXnPp-hqKIN6rPqX-BvrVWJTNXYJyQFtZoAa9AZzebPUxOO5hZGjQ3vqQDTOtxiVvR3wn62NHwXnb1q6Ary3sL3o0WSt89w8qsEGTS$)

The research article is co-authored by academics at the University of
Birmingham and the Royal Bristol Hospital for Children, led by Christopher
McConville, Associate Professor or Pharmaceutics at the University of
Birmingham and also Chief Scientific Officer at CRISM Therapeutics.  Cancers
is a peer reviewed, open access, medical journal published by MDPI covering
all fields of oncology.

The safety of the local administration of irinotecan to the resection margin
confirmed by this research article validates CRISM's decision to use
irinotecan in ChemoSeed as a treatment for high grade gliomas and is expected
to support its clinical trial application.  Furthermore, the article
concludes that sustaining the delivery of irinotecan at the resection margin
using an implantable device, such as ChemoSeed, could improve survival rates
in glioblastoma patients.

Commenting on the article in the peer reviewed journal, CRISM CEO Andrew Webb
said: "The publication of this paper validates CRISM's drug delivery approach
to administer irinotecan locally into the resection margin and we are pleased
that this method of drug delivery is receiving greater recognition within the
oncology community.  In addition, this validation will support our clinical
trial application which remains on track for H2 this year."

 

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl                         CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
high-grade glioma, ChemoSeeds can be implanted during surgery thereby
bypassing the blood brain barrier, which prevents other treatments from being
able to reach the tumour and be effective.

CRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed®
in high-grade glioma.  Based on preclinical data, the Tessa Jowell BRAIN
MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform
clinical trial which is an efficient and cost-effective clinical development
opportunity.

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUCABUPCGAP